TAVR for Aortic Valve Disease

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

NCT Number	NCT05439863
Lead Sponsor	Nanjing First Hospital, Nanjing Medical University
Conditions	Aortic Valve Disease
Enrollment	5,000 participants
Start Date	2022-07-01
Primary Completion	2032-12-30 (estimated)
Study Completion	2037-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-11-15